Tag: anemia and other blood disorder drugs market analysis

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Anemia And Other Blood Disorder Drugs Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The anemia and other blood disorder drugs market has shown robust growth over recent years. Its size is expected to increase from $12.46 billion in 2025 to $13.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This market’s past expansion can be linked to several factors, including the frequent occurrence of iron deficiency anemia, the prevalence of chronic kidney disease, the necessity of blood transfusions, the sustained application of ESAs, and the adoption of established hematology treatment protocols.

The anemia and other blood disorder drugs market is anticipated to experience substantial expansion in the coming years. It is projected to reach $16.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by factors such as the increasing adoption of gene therapy, a growing aging population, heightened awareness of blood disorders, the establishment of more specialty hematology clinics, and enhanced diagnostic rates. Key developments expected during this forecast period encompass a rising incidence of chronic blood disorders, a greater reliance on injectable therapies, the broader application of gene therapy for rare anemias, an increased emphasis on personalized hematology treatments, and better availability of crucial blood disorder medications.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anemia And Other Blood Disorder Drugs Market Development Factors: What’s Supporting Demand?

The increasing need for individualized healthcare approaches is anticipated to fuel the expansion of the anemia and other blood disorder drugs market in the future. This medical strategy, known as personalized medicine, utilizes a person’s unique genetic information to inform choices regarding disease prevention, identification, and therapy. The heightened call for personalized medicine stems from its capacity to provide highly effective, specific treatments, leading to better patient results and enduring well-being. Within the anemia and other blood disorder drugs market, personalized care is facilitated through customized treatment strategies that target distinct genetic or molecular traits of these conditions. For example, data from May 2024, provided by the American Psychiatric Association, a US-based non-profit entity, indicates that 43% of adults reported increased anxiety compared to the previous year, rising from 37% in 2023 and 32% in 2022. Consequently, the expanding requirement for personalized medicine is stimulating the development of the anemia and other blood disorder drugs market.

Anemia And Other Blood Disorder Drugs Market Segment Landscape: Which Areas Lead Development?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

Anemia And Other Blood Disorder Drugs Market Transformation Trends: What Innovations Are Driving Change?

Leading companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to enhance therapeutic results, broaden treatment possibilities, and strengthen their competitive standing. Novel medications are defined as advanced pharmaceutical therapies that present new mechanisms of action, superior effectiveness, or improved safety profiles compared to existing treatments, addressing unmet needs in conditions such as anemia and myelodysplastic syndromes. For example, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl for the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marked the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this specific setting, supported by Phase 3 COMMANDS trial data revealing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

Anemia And Other Blood Disorder Drugs Market Industry Leaders And Competitive Landscape

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

View The Full Anemia And Other Blood Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Anemia And Other Blood Disorder Drugs Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Anemia And Other Blood Disorder Drugs Market Expected To Reach $16.87 Billion By 2030 At 6.5% CAGR

The market for anemia and other blood disorder medications has experienced robust expansion in recent times. Projections indicate a rise from $12.46 billion in 2025 to $13.14 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. Historical growth was driven by several factors, including a significant occurrence of iron deficiency anemia, the widespread presence of chronic kidney disease, a heavy dependence on blood transfusions, the extended utilization of erythropoiesis-stimulating agents (ESAs), and the existence of well-established protocols for hematology treatment.

Over the coming years, the market for drugs treating anemia and other blood disorders is anticipated to experience robust expansion. Projections indicate it will reach a value of $16.88 billion by 2030, with a compound annual growth rate (CAGR) of 6.5%. Several factors are expected to drive this growth during the forecast period, including the increasing adoption of gene therapy, the growing proportion of elderly individuals, heightened awareness surrounding blood disorders, the proliferation of specialized hematology clinics, and enhanced diagnostic rates. Key developments shaping this period comprise the growing incidence of chronic blood conditions, an uptick in the application of injectable treatments, the advancement of gene-based solutions for rare anemias, a heightened emphasis on personalized hematology approaches, and better accessibility to fundamental medications for blood disorders.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anemia And Other Blood Disorder Drugs Market Growth Drivers And Industry Catalysts

The growing need for tailored medical treatments is anticipated to drive expansion in the market for drugs addressing anemia and other blood-related conditions. This approach, known as personalized medicine, relies on an individual’s genetic information to inform decisions about prevention, diagnosis, and therapy. Its increasing popularity stems from its capacity to provide more precise and effective treatments, ultimately enhancing patient results and long-term wellness. In the field of blood disorders, this market facilitates customized care by designing treatment strategies that target the distinct genetic or molecular features of each condition. For example, data from the American Psychiatric Association—a nonprofit organization based in the United States—showed that in May 2024, 43% of adults reported higher anxiety levels compared to the prior year, up from 37% in 2023 and 32% in 2022. As a result, the rising preference for personalized medicine is fueling growth in the anemia and blood disorder drugs market.

Anemia And Other Blood Disorder Drugs Market Segment Outlook: Which Categories Are Expanding The Fastest?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

Anemia And Other Blood Disorder Drugs Market Trends Influencing Long-Term Demand

Major pharmaceutical players in the anemia and related blood disorder drugs market are intensively concentrating on developing innovative treatments to enhance patient outcomes, diversify available therapeutic choices, and bolster their market standing. These novel pharmaceuticals represent cutting-edge therapies that introduce fresh mechanisms of action, deliver stronger effectiveness, or feature more favorable safety profiles when weighed against standard care, thereby addressing unfulfilled medical requirements in disorders like anemia and myelodysplastic syndromes. A notable example occurred in August 2023, when Bristol-Myers Squibb Company, headquartered in the United States, secured FDA approval for Reblozyl as the initial therapy for anemia in adults with lower-risk myelodysplastic syndromes. This achievement marked the first drug to prove its superiority over an erythropoiesis-stimulating agent in this clinical context, with findings from the Phase 3 COMMANDS trial revealing that nearly double the proportion of patients on Reblozyl reached at least 12 weeks free from blood transfusions while also showing concurrent hemoglobin improvements compared to those administered Epoetin alfa.

Anemia And Other Blood Disorder Drugs Market Key Companies And Competitive Benchmarking

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Access The Complete Anemia And Other Blood Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Anemia And Other Blood Disorder Drugs Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Anemia And Other Blood Disorder Drugs Market Progress Through 2030?

The anemia and other blood disorder drugs market size has observed strong growth recently. It is projected to increase from $12.46 billion in 2025 to $13.14 billion in 2026, displaying a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed in the past can be linked to factors such as a high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, the dependence on blood transfusions, the prolonged application of esAs, and established hematology treatment protocols.

The anemia and other blood disorder drugs market size is anticipated to experience significant expansion over the coming years. It is projected to grow to $16.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. This growth within the forecast period is attributed to factors such as the increasing adoption of gene therapy, a rising aging population, greater awareness of blood disorders, the expansion of specialty hematology clinics, and improved diagnostic rates. Prominent trends for the forecast period include the increasing prevalence of chronic blood disorders, a growing use of injectable therapies, the expansion of gene therapy for rare anemias, an increasing focus on personalized hematology treatments, and enhanced access to essential blood disorder drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

Which Growth Drivers Are Expected To Support The Anemia And Other Blood Disorder Drugs Market Forward?

The increasing demand for personalized medicine is anticipated to drive the future growth of the anemia and other blood disorder drugs market. Personalized medicine is a medical methodology that leverages an individual’s genetic profile to inform prevention, diagnosis, and treatment strategies. The rise in demand for personalized medicine stems from its capability to deliver more effective, targeted therapies that enhance patient outcomes and long-term health. The anemia and other blood disorder drugs market supports personalized care by enabling individualized treatment plans designed to address the specific genetic or molecular characteristics of blood disorders. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults report feeling more anxious than they did the year before, an increase from 37% in 2023 and 32% in 2022. Consequently, the escalating demand for personalized medicine is propelling the expansion of the anemia and other blood disorder drugs market.

What Are The Core Segment Classifications In The Anemia And Other Blood Disorder Drugs Market?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

Which Trends Are Guiding The Development Of The Anemia And Other Blood Disorder Drugs Market?

Major companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to elevate therapeutic outcomes, expand treatment options, and strengthen their competitive standing. Novel medications are defined as advanced pharmaceutical therapies that offer new mechanisms of action, superior effectiveness, or enhanced safety profiles compared to existing treatments, thereby addressing unmet medical needs in conditions such as anemia and myelodysplastic syndromes. For example, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received FDA approval for Reblozyl for use as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marked the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, supported by Phase 3 COMMANDS trial data revealing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

Which Organizations Are Involved In The Anemia And Other Blood Disorder Drugs Market?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Access The Complete Anemia And Other Blood Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Region Contributes The Most To The Anemia And Other Blood Disorder Drugs Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Anemia And Other Blood Disorder Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Anemia And Other Blood Disorder Drugs Market Expected To Scale Between 2026 And 2030?

The anemia and other blood disorder drugs market size has demonstrated significant growth in recent years. It is anticipated to expand from $12.46 billion in 2025 to $13.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This market’s historical expansion can be linked to factors including the high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, the reliance on blood transfusions, the long-standing use of ESAs, and established hematology treatment protocols.

The market for drugs addressing anemia and other blood disorders is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach a value of $16.88 billion, demonstrating a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by several factors, including the greater adoption of gene therapy, a growing elderly demographic, heightened public awareness of blood conditions, the proliferation of specialized hematology clinics, and more effective diagnostic procedures. Key developments expected during this period encompass an escalating incidence of chronic blood disorders, a greater reliance on injectable treatments, the broadening application of gene therapy for uncommon anemias, an enhanced emphasis on customized hematology solutions, and better availability of crucial blood disorder medications.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Significant Factors Are Influencing The Anemia And Other Blood Disorder Drugs Market Expansion?

The increasing need for personalized medicine is anticipated to boost the expansion of the anemia and other blood disorder drugs market going forward. Personalized medicine is a healthcare strategy that leverages an individual’s genetic profile to direct decisions regarding prevention, diagnosis, and treatment. The escalating desire for personalized medicine stems from its capability to deliver more efficacious, targeted therapies, which leads to improved patient outcomes and long-term health. The anemia and other blood disorder drugs market supports individualized care by enabling tailored treatment plans that address the unique genetic or molecular characteristics of blood disorders. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults report feeling more anxious than they did the year before, an increase from 37% in 2023 and 32% in 2022. Consequently, the rising demand for personalized medicine is propelling the growth of the anemia and other blood disorder drugs market.

How Is Segmentation Applied In The Anemia And Other Blood Disorder Drugs Market Segment Analysis?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

What Trends Are Affecting The Growth Of The Anemia And Other Blood Disorder Drugs Market?

Major companies operating within the anemia and other blood disorder drugs market are prioritizing the introduction of new medications to enhance therapeutic results, broaden available treatments, and solidify their market standing. These novel medications represent innovative pharmaceutical solutions that offer fresh mechanisms of action, greater effectiveness, or enhanced safety profiles compared to current treatments, addressing critical needs in conditions like anemia and myelodysplastic syndromes. For example, in August 2023, the US-based pharmaceutical firm Bristol-Myers Squibb Company obtained FDA approval for Reblozyl. This drug is now approved as a first-line therapy for anemia in adults suffering from lower-risk myelodysplastic syndromes, marking it as the initial treatment to demonstrate superior performance over an erythropoiesis-stimulating agent in this particular context. This was supported by data from the Phase 3 COMMANDS trial, which indicated that almost twice as many patients treated with Reblozyl achieved at least 12 weeks of transfusion independence along with concurrent hemoglobin improvement, in contrast to those receiving Epoetin alfa.

Who Are The Companies Participating In The Anemia And Other Blood Disorder Drugs Market Environment?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Get The Full Anemia And Other Blood Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Region Accounts For The Largest Portion Of The Anemia And Other Blood Disorder Drugs Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Anemia And Other Blood Disorder Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Anemia And Other Blood Disorder Drugs Market Expected To Scale Between 2026 And 2030?

The anemia and other blood disorder drugs market size has demonstrated significant growth in recent years. It is anticipated to expand from $12.46 billion in 2025 to $13.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This market’s historical expansion can be linked to factors including the high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, the reliance on blood transfusions, the long-standing use of ESAs, and established hematology treatment protocols.

The market for drugs addressing anemia and other blood disorders is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach a value of $16.88 billion, demonstrating a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by several factors, including the greater adoption of gene therapy, a growing elderly demographic, heightened public awareness of blood conditions, the proliferation of specialized hematology clinics, and more effective diagnostic procedures. Key developments expected during this period encompass an escalating incidence of chronic blood disorders, a greater reliance on injectable treatments, the broadening application of gene therapy for uncommon anemias, an enhanced emphasis on customized hematology solutions, and better availability of crucial blood disorder medications.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Significant Factors Are Influencing The Anemia And Other Blood Disorder Drugs Market Expansion?

The increasing need for personalized medicine is anticipated to boost the expansion of the anemia and other blood disorder drugs market going forward. Personalized medicine is a healthcare strategy that leverages an individual’s genetic profile to direct decisions regarding prevention, diagnosis, and treatment. The escalating desire for personalized medicine stems from its capability to deliver more efficacious, targeted therapies, which leads to improved patient outcomes and long-term health. The anemia and other blood disorder drugs market supports individualized care by enabling tailored treatment plans that address the unique genetic or molecular characteristics of blood disorders. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults report feeling more anxious than they did the year before, an increase from 37% in 2023 and 32% in 2022. Consequently, the rising demand for personalized medicine is propelling the growth of the anemia and other blood disorder drugs market.

How Is Segmentation Applied In The Anemia And Other Blood Disorder Drugs Market Segment Analysis?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

What Trends Are Affecting The Growth Of The Anemia And Other Blood Disorder Drugs Market?

Major companies operating within the anemia and other blood disorder drugs market are prioritizing the introduction of new medications to enhance therapeutic results, broaden available treatments, and solidify their market standing. These novel medications represent innovative pharmaceutical solutions that offer fresh mechanisms of action, greater effectiveness, or enhanced safety profiles compared to current treatments, addressing critical needs in conditions like anemia and myelodysplastic syndromes. For example, in August 2023, the US-based pharmaceutical firm Bristol-Myers Squibb Company obtained FDA approval for Reblozyl. This drug is now approved as a first-line therapy for anemia in adults suffering from lower-risk myelodysplastic syndromes, marking it as the initial treatment to demonstrate superior performance over an erythropoiesis-stimulating agent in this particular context. This was supported by data from the Phase 3 COMMANDS trial, which indicated that almost twice as many patients treated with Reblozyl achieved at least 12 weeks of transfusion independence along with concurrent hemoglobin improvement, in contrast to those receiving Epoetin alfa.

Who Are The Companies Participating In The Anemia And Other Blood Disorder Drugs Market Environment?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Get The Full Anemia And Other Blood Disorder Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Region Accounts For The Largest Portion Of The Anemia And Other Blood Disorder Drugs Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Anemia And Other Blood Disorder Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Anemia And Other Blood Disorder Drugs Market By The End Of 2030?

The anemia and other blood disorder drugs market size has shown robust expansion in recent years. It is projected to expand from $12.46 billion in 2025 to $13.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. This historical growth can be linked to several key factors, including the high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, reliance on blood transfusions, long-standing use of esAs, and established hematology treatment protocols.

The anemia and other blood disorder drugs market is anticipated to show significant expansion in the coming years. Its value is projected to reach $16.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.5%. This forecasted growth is primarily fueled by increased adoption of gene therapy, an expanding aging population, heightened awareness of blood disorders, the establishment of more specialty hematology clinics, and better diagnostic rates. Noteworthy trends during this period encompass a rise in the prevalence of chronic blood disorders, greater utilization of injectable therapies, the broader application of gene therapy for rare anemias, an intensifying focus on personalized hematology treatments, and improved access to vital blood disorder medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Drivers Are Shaping The Future Growth Of The Anemia And Other Blood Disorder Drugs Market?

The increasing demand for personalized medicine is projected to drive the expansion of the anemia and other blood disorder drugs market in the future. Personalized medicine represents a healthcare strategy that utilizes an individual’s genetic blueprint to direct choices in prevention, diagnosis, and treatment. The escalating need for personalized medicine stems from its capacity to offer more potent and precisely targeted therapies, which in turn enhance patient outcomes and promote enduring health. The anemia and other blood disorder drugs market facilitates personalized care by allowing for customized treatment regimens that target specific genetic or molecular attributes of blood conditions. For example, in May 2024, data from the American Psychiatric Association, a US-based non-profit organization, showed that 43% of adults reported feeling more anxious than in the prior year, an increase from 37% in 2023 and 32% in 2022. Thus, the growing inclination towards personalized medicine is fostering the development of the anemia and other blood disorder drugs market.

Which Segment Classifications Shape The Anemia And Other Blood Disorder Drugs Market?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

How Are Trends Impacting The Anemia And Other Blood Disorder Drugs Market?

Major companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to enhance therapeutic outcomes, expand treatment possibilities, and reinforce their competitive stance. Novel medications are defined as pioneering pharmaceutical treatments that offer new modes of action, improved effectiveness, or enhanced safety profiles compared to existing therapies, thereby addressing unfulfilled medical needs in conditions such as anemia and myelodysplastic syndromes. For instance, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marks the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, corroborated by Phase 3 COMMANDS trial data showing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

Which Companies Are Expanding Their Footprint In The Anemia And Other Blood Disorder Drugs Market?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Read the full anemia and other blood disorder drugs market report here:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Geographic Regions Are Influencing Demand In The Anemia And Other Blood Disorder Drugs Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anemia And Other Blood Disorder Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Anemia And Other Blood Disorder Drugs Market By The End Of 2030?

The anemia and other blood disorder drugs market size has shown robust expansion in recent years. It is projected to expand from $12.46 billion in 2025 to $13.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. This historical growth can be linked to several key factors, including the high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, reliance on blood transfusions, long-standing use of esAs, and established hematology treatment protocols.

The anemia and other blood disorder drugs market is anticipated to show significant expansion in the coming years. Its value is projected to reach $16.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.5%. This forecasted growth is primarily fueled by increased adoption of gene therapy, an expanding aging population, heightened awareness of blood disorders, the establishment of more specialty hematology clinics, and better diagnostic rates. Noteworthy trends during this period encompass a rise in the prevalence of chronic blood disorders, greater utilization of injectable therapies, the broader application of gene therapy for rare anemias, an intensifying focus on personalized hematology treatments, and improved access to vital blood disorder medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Drivers Are Shaping The Future Growth Of The Anemia And Other Blood Disorder Drugs Market?

The increasing demand for personalized medicine is projected to drive the expansion of the anemia and other blood disorder drugs market in the future. Personalized medicine represents a healthcare strategy that utilizes an individual’s genetic blueprint to direct choices in prevention, diagnosis, and treatment. The escalating need for personalized medicine stems from its capacity to offer more potent and precisely targeted therapies, which in turn enhance patient outcomes and promote enduring health. The anemia and other blood disorder drugs market facilitates personalized care by allowing for customized treatment regimens that target specific genetic or molecular attributes of blood conditions. For example, in May 2024, data from the American Psychiatric Association, a US-based non-profit organization, showed that 43% of adults reported feeling more anxious than in the prior year, an increase from 37% in 2023 and 32% in 2022. Thus, the growing inclination towards personalized medicine is fostering the development of the anemia and other blood disorder drugs market.

Which Segment Classifications Shape The Anemia And Other Blood Disorder Drugs Market?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

How Are Trends Impacting The Anemia And Other Blood Disorder Drugs Market?

Major companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to enhance therapeutic outcomes, expand treatment possibilities, and reinforce their competitive stance. Novel medications are defined as pioneering pharmaceutical treatments that offer new modes of action, improved effectiveness, or enhanced safety profiles compared to existing therapies, thereby addressing unfulfilled medical needs in conditions such as anemia and myelodysplastic syndromes. For instance, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marks the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, corroborated by Phase 3 COMMANDS trial data showing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

Which Companies Are Expanding Their Footprint In The Anemia And Other Blood Disorder Drugs Market?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Read the full anemia and other blood disorder drugs market report here:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Geographic Regions Are Influencing Demand In The Anemia And Other Blood Disorder Drugs Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anemia And Other Blood Disorder Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Anemia And Other Blood Disorder Drugs Market By The End Of 2030?

The anemia and other blood disorder drugs market size has shown robust expansion in recent years. It is projected to expand from $12.46 billion in 2025 to $13.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. This historical growth can be linked to several key factors, including the high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, reliance on blood transfusions, long-standing use of esAs, and established hematology treatment protocols.

The anemia and other blood disorder drugs market is anticipated to show significant expansion in the coming years. Its value is projected to reach $16.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.5%. This forecasted growth is primarily fueled by increased adoption of gene therapy, an expanding aging population, heightened awareness of blood disorders, the establishment of more specialty hematology clinics, and better diagnostic rates. Noteworthy trends during this period encompass a rise in the prevalence of chronic blood disorders, greater utilization of injectable therapies, the broader application of gene therapy for rare anemias, an intensifying focus on personalized hematology treatments, and improved access to vital blood disorder medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Drivers Are Shaping The Future Growth Of The Anemia And Other Blood Disorder Drugs Market?

The increasing demand for personalized medicine is projected to drive the expansion of the anemia and other blood disorder drugs market in the future. Personalized medicine represents a healthcare strategy that utilizes an individual’s genetic blueprint to direct choices in prevention, diagnosis, and treatment. The escalating need for personalized medicine stems from its capacity to offer more potent and precisely targeted therapies, which in turn enhance patient outcomes and promote enduring health. The anemia and other blood disorder drugs market facilitates personalized care by allowing for customized treatment regimens that target specific genetic or molecular attributes of blood conditions. For example, in May 2024, data from the American Psychiatric Association, a US-based non-profit organization, showed that 43% of adults reported feeling more anxious than in the prior year, an increase from 37% in 2023 and 32% in 2022. Thus, the growing inclination towards personalized medicine is fostering the development of the anemia and other blood disorder drugs market.

Which Segment Classifications Shape The Anemia And Other Blood Disorder Drugs Market?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

How Are Trends Impacting The Anemia And Other Blood Disorder Drugs Market?

Major companies in the anemia and other blood disorder drugs market are concentrating on introducing innovative medications to enhance therapeutic outcomes, expand treatment possibilities, and reinforce their competitive stance. Novel medications are defined as pioneering pharmaceutical treatments that offer new modes of action, improved effectiveness, or enhanced safety profiles compared to existing therapies, thereby addressing unfulfilled medical needs in conditions such as anemia and myelodysplastic syndromes. For instance, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marks the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, corroborated by Phase 3 COMMANDS trial data showing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

Which Companies Are Expanding Their Footprint In The Anemia And Other Blood Disorder Drugs Market?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Read the full anemia and other blood disorder drugs market report here:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Geographic Regions Are Influencing Demand In The Anemia And Other Blood Disorder Drugs Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anemia And Other Blood Disorder Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the anemia and other blood disorder drugs market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Anemia And Other Blood Disorder Drugs Market in 2030?

The anemia and other blood disorder drugs market size has demonstrated significant expansion in recent years. It is anticipated to grow from $12.46 billion in 2025 to $13.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The historical rise in this market can be ascribed to a high incidence of iron deficiency anemia, the prevalence of chronic kidney disease, the reliance on blood transfusions, the long-standing use of ESAs, and established hematology treatment protocols.

The anemia and other blood disorder drugs market size is projected to experience significant expansion over the next few years. It is forecast to reach $16.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period is attributable to factors such as the increasing adoption of gene therapy, a rising aging population, greater awareness of blood disorders, the proliferation of specialty hematology clinics, and improved diagnostic rates. Prominent trends expected in this period include the increasing prevalence of chronic blood disorders, a growing reliance on injectable therapies, the wider application of gene therapy for rare anemias, an intensified focus on personalized hematology treatments, and enhanced access to essential blood disorder drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Drivers Are Influencing Production Trends In The Anemia And Other Blood Disorder Drugs Market?

The increasing need for personalized medicine is anticipated to boost the expansion of the anemia and other blood disorder drugs market in the future. This medical strategy tailors prevention, diagnosis, and treatment decisions based on an individual’s unique genetic makeup. The growing interest in personalized medicine stems from its capacity to offer more precise and effective treatments, leading to better patient results and enhanced long-term well-being. The anemia and other blood disorder drugs market facilitates personalized care through customized treatment regimens designed to target the distinct genetic or molecular traits of various blood disorders. As an illustration, data from May 2024 by the American Psychiatric Association, a US-based non-profit organization, indicates that 43% of adults reported increased anxiety compared to the previous year, an uptick from 37% in 2023 and 32% in 2022. Consequently, the increasing need for personalized medicine is a key factor propelling the expansion of the anemia and other blood disorder drugs market.

Which Segment Groups Are Influencing The Anemia And Other Blood Disorder Drugs Market?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

Which Market Trends Are Opening Growth Opportunities In The Anemia And Other Blood Disorder Drugs Market?

Leading companies involved in the anemia and other blood disorder drugs market are prioritizing the introduction of novel medications, with the goal of enhancing therapeutic outcomes, expanding treatment possibilities, and strengthening their market position. These novel medications represent innovative pharmaceutical therapies that present new mechanisms of action, superior efficacy, or improved safety profiles when compared to existing treatments, addressing unmet medical needs in conditions such as anemia and myelodysplastic syndromes. For example, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, obtained FDA approval for Reblozyl for use as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes. This marks the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, a finding supported by Phase 3 COMMANDS trial data which showed that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence coupled with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

Who Are The Core Companies Influencing Trends In The Anemia And Other Blood Disorder Drugs Market?

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Regions Are Projected To Dominate The Anemia And Other Blood Disorder Drugs Market In The Coming Years?

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Anemia And Other Blood Disorder Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp

Browse Through More Reports Similar to the Global Anemia And Other Blood Disorder Drugs Market 2026, By The Business Research Company

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmaceutical excipients market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Pharmaceutical Excipients Industry By 2029?

The anemia and other blood disorder drugs market size has experienced strong growth in recent years. It is expected to expand from $11.81 billion in 2024 to $12.46 billion in 2025, progressing at a compound annual growth rate (CAGR) of 5.5%. This historical growth can be attributed to factors such as disease prevalence, global health initiatives, an aging population, pharmaceutical innovation, and patient awareness.

The anemia and other blood disorder drugs market size is anticipated to undergo significant expansion in the coming years. It is forecast to increase to $15.82 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.1%. The expansion during the projected period can be attributed to factors such as emerging markets, global demographic shifts, and various economic considerations. Noteworthy trends for the forecast period include continued research and development, ongoing technological advances, the emergence of biologics and targeted therapies, the development of gene therapies, the implementation of telemedicine and remote monitoring, the granting of orphan drug designations, and a prevalence of mergers and acquisitions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2465&type=smp

What Major Drivers Are Impacting The Pharmaceutical Excipients Market?

The global market is significantly propelled by the rising incidence of anemia across the world’s population. Poor lifestyle choices, shifting dietary patterns, and heightened stress levels have led to a global rise in anemia cases. For example, anemia is recognized as the most common ailment among individuals over 65 years old, with its prevalence reaching approximately 17%. Furthermore, the World Bank indicated that anemia stands as the 8th primary cause of illness among women and younger demographics. This escalating prevalence of anemia directly fuels the anemia and other blood disorder drugs market.

Which Segment Categories Are Driving Maximum Growth In The Pharmaceutical Excipients Market?

The anemia and other blood disorder drugs market covered in this report is segmented –

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy

Subsegments:

1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods

2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion

3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs

4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

Which Long-Term Trends Will Play A Crucial Role In The Pharmaceutical Excipients Market?

Entities within the anemia and other blood disorder drugs market are forging partnerships with government bodies to advance the development and commercialization of specific medications through shared knowledge, technology, and financial resources. These collaborations are additionally beneficial for companies, particularly when confronting expiring licenses and a stringent regulatory environment. For example, in March 2023, Disc Medicine announced a collaboration with the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) to conduct Phase 1/2 and Phase 2 clinical trials of biopterin for patients with Diamond-Blackfan Anemia (DBA), with the aim of treating adult patients experiencing iron deficiency anemia. The NIH will be responsible for conducting and funding these studies under a cooperative research and development agreement (CRADA).

Who Are The Dominant Players In The Pharmaceutical Excipients Market Today?

Major companies operating in the anemia and other blood disorder drugs market include Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Which Region Is At The Forefront Of Innovation In The Pharmaceutical Excipients Market?

North America was the largest region in the anemia and other blood disorder drugs market in 2024. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=2465&type=smp

Browse Through More Reports Similar to the Global Pharmaceutical Excipients Market 2025, By The Business Research Company

Anti Infective Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Hospital Acquired Infections Testing Kits Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Anti Viral Drug Therapy Market 2025

https://www.thebusinessresearchcompany.com/report/anti-viral-drug-therapy-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model